An isocratic high performance liquid chromatography (HPLC) assay for moxifloxacin, a new 8-methoxyquinolone

Moxifloxacin (BAY 12-8039) is a new 8-methoxyquinolone with enhanced anti-Gram-positive activity in vitro compared with ciprofloxacin and ofloxacin. In-vitro sensitivity results have thus far indicated a potential clinical role in the treatment of community-acquired respiratory tract infection. The mean peak plasma concentration (T sub(max) = 1 h) after a 600 mg oral dose has been reported to be around 4 mg/L, with a steady state trough concentration of 1.0 mg/L. A standard dose of 400 mg once daily has been proposed for moxifloxacin.